Report : South & Central America Fish Vaccines Market Forecast to 2030 - Regional Analysis - by Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Recombinant Vector Vaccine, and Others), Application (Bacterial Infection, Viral Infection, and Parasitic), Route of Administration (Injection Vaccine, Immersion Vaccine, and Oral Vaccine), and Species (Salmon, Trout, Tilapia, and Others)
At 7.3% CAGR, the South & Central America Fish Vaccines Market is Projected to be worth US$ 37.35 million by 2030, says Business Market Insights
According to Business Market Insights research, the South & Central America fish vaccines market was valued at US$ 21.25 million in 2022 and is expected to reach US$ 37.35 million by 2030, registering a CAGR of 7.3% from 2022 to 2030. Government initiatives to develop aquaculture industry and surging demand for aquatic animal-derived food products are the critical factors attributed to the South & Central America fish vaccines market expansion.
Diversifying into new fish species, particularly marine fish, is a trend in the aquaculture sector. Farms across the world are increasingly relying on vaccinations to manage animal health. The development of novel pathogens with extensive antigenic diversity may also reduce the effectiveness of conventional vaccines. This motivates vaccine researchers to look into new techniques for creating potent vaccines for aquaculture. Subunit or recombinant DNA/RNA particle vaccines may have been created using modern vaccine technology, which is focused on specific pathogen components. Finding new vaccine candidates to fight fish pathogens such as mycotic and parasitic agents is made possible by recent advancements in vaccines and vaccinology. The development and production of fish vaccines can do rapidly with the help of new techniques in genetics, immunology, and biotechnology. These techniques include the use of genetically engineered vectors, recombinant vaccines, and DNA vaccines. DNA vaccine technology provides significant protection against fish diseases. Targeting the construct and/or transgene to antigen-receptor cells is a promising way to improve the DNA vaccine's effectiveness against other viral diseases. Molecular assemblies can be used to target dendritic cells (DC) and antigen-presenting cells (APC) in DNA vaccines, producing immune responses as a result. Another tactic is to encapsulate the DNA vaccine in specific carriers to increase transgene and MHC expression. The development of novel vaccines known as recombinant DNA-based vaccine or new-generation vaccines has made extensive use of R DNA technology. Recombinant immunogenic protein vaccines or epitopes purified from vectors carrying the gene of interest produced in prokaryotic or eukaryotic expression systems, peptide vaccines, live vaccines produced by defined genetic manipulations, and microbial vectors carrying gene coding for immunogenic protein and DNA vaccines are among the types of vaccines based on recombinant DNA technology that have been developed. Recombinant vaccines have the advantage of closely simulating naturally occurring infections, which aids in triggering a potent immune response in the treated fish. They can also be mass produced easily.
On the contrary, stringent regulations for approval of vaccine hurdles the growth of South & Central America fish vaccines market.
Based on vaccine type, the South & Central America fish vaccines market is categorized into inactivated vaccines, live attenuated vaccines, subunit vaccines, recombinant vector vaccine, and others. The inactivated vaccines segment held 71.4% market share in 2022, amassing US$ 15.16 million. It is projected to garner US$ 26.99 million by 2030 to expand at 7.5% CAGR during 2022-2030.
Based on application, the South & Central America fish vaccines market is categorized into bacterial infection, viral infection, and parasitic. The bacterial infection segment held 80.8% share of South & Central America fish vaccines market in 2022, amassing US$ 17.16 million. It is projected to garner US$ 30.68 million by 2030 to expand at 7.5% CAGR during 2022-2030.
Based on route of administration, the South & Central America fish vaccines market is categorized into injection vaccine, immersion vaccine, and oral vaccine. The injection vaccine segment held 57.6% share of South & Central America fish vaccines market in 2022, amassing US$ 12.25 million. It is projected to garner US$ 21.47 million by 2030 to expand at 7.3% CAGR during 2022-2030.
Based on species, the South & Central America fish vaccines market is categorized into salmon, trout, tilapia, and others. The salmon segment held 66.0% share of South & Central America fish vaccines market in 2022, amassing US$ 14.01 million. It is projected to garner US$ 24.51 million by 2030 to expand at 7.2% CAGR during 2022-2030.
Based on country, the South & Central America fish vaccines market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that the Rest of South & Central America captured 52.7% share of South & Central America fish vaccines market in 2022. It was assessed at US$ 11.19 million in 2022 and is likely to hit US$ 19.91 million by 2030, exhibiting a CAGR of 7.5% during 2022-2030.
Key players operating in the South & Central America fish vaccines market are Elanco Animal Health Inc, Hipra SA, Merck & Co Inc., Phibro Animal Health Corp, Vaxxinova International BV, and Zoetis Inc., among others.
- In Aug 2020, Elanco Closes Acquisition of Bayer Animal Health.
- In Mar 2020, HIPRA and Skretting combine expertise to tackle devasting trout disease.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com